Drug Discovery
Drug Discovery covers where GLP-1 came from and where it’s going. Single-agonist (semaglutide), dual-agonist (tirzepatide), triple-agonist (retatrutide in trials), and oral small-molecule (orforglipron, just approved as Foundayo) — each represents a different bet on maximizing efficacy while managing side effects. We explain mechanisms and track the late-stage pipeline.
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Latest in Drug Discovery
GLP-1 in 2026: 5 Big Changes Coming Soon
A new pill, a far more powerful drug in trials, a Medicare pilot, a tightening line on compounding. The GLP-1…
Compounded Semaglutide from $147/month
More from Drug Discovery
GLP-1 Drugs 101: How Ozempic & Friends Work
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
New drug candidates for cystic fibrosis
Cystic Fibrosis (CF) affects about 30,000 people in the United States and approximately 70,000 people…
What is a Peptide Library?
The combinatorial peptide library is a powerful method in which a vast number of various…
Histone deacetylase inhibitors
Histone deacetylases (HDACs) are enzymes that catalyze the deacetylation of lysine residues located in the…
What is a Compound Library?
A compound library is a collection of real stored chemicals and/or virtual chemical compounds. The…